Comparing the effects of insulin glargine and thiazolidinediones on plasma lipids in type 2 diabetes

A patient-level pooled analysis

Ajay Chaudhuri, Julio Rosenstock, Andres Digenio, Luigi Meneghini, Priscilla Hollander, Janet B. McGill, Paresh Dandona, John Ilgenfritz, Matthew Riddle

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Background: The prevalence of dyslipidaemia and the risk of cardiovascular disease are elevated in patients with type 2 diabetes. This analysis compared the effects of insulin glargine versus thiazolidinediones (TZDs) on lipid profiles. Methods: Patient-level data were pooled from two randomized clinical studies. The population included 552 men and women aged >18years, diagnosed with type 2 diabetes for at least 6months, on metformin and/or sulphonylurea, and with A 1C ≥7.5% and <12.0% at screening. Lipid outcome measures included change from baseline in lipid levels [low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), non-high-density lipoprotein cholesterol (non-HDL-C), total cholesterol, triglycerides, and free fatty acids] and attainment of lipid goals for LDL-C, non-HDL-C, and triglycerides. Results: Both insulin glargine and TZDs improved lipid profiles from baseline values. Compared with TZDs, treatment with insulin glargine led to 7.9% greater reduction in LDL-C (p<0.0003), 7.5% greater reduction in non-HDL-C (p<0.0001), and 7.8% greater reduction in total cholesterol (p<0.0001), whereas the HDL-C increase with TZD was 7.6% greater than that with insulin glargine (p<0.0001). The percentage of patients attaining the lipid goals was comparable between insulin glargine and pioglitazone, but lower for rosiglitazone. Insulin glargine improved glycaemic control more than TZDs; however, insulin glargine caused more hypoglycaemia. Treatment with TZDs caused more weight gain and peripheral oedema. Conclusion: These findings suggest that the favourable effects of insulin glargine on plasma lipid profiles should be considered among the advantages of treatment with insulin glargine as they are for TZDs.

Original languageEnglish (US)
Pages (from-to)258-267
Number of pages10
JournalDiabetes/Metabolism Research and Reviews
Volume28
Issue number3
DOIs
StatePublished - Mar 2012

Fingerprint

Thiazolidinediones
Type 2 Diabetes Mellitus
Lipids
LDL Cholesterol
rosiglitazone
pioglitazone
HDL Cholesterol
Cholesterol
Insulin Glargine
Metformin
Dyslipidemias
Hypoglycemia
Nonesterified Fatty Acids
Weight Gain
Edema
Triglycerides
Cardiovascular Diseases
Therapeutics
Outcome Assessment (Health Care)

Keywords

  • Insulin glargine
  • Lipids
  • Thiazolidinediones
  • Type 2 diabetes

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Internal Medicine

Cite this

Comparing the effects of insulin glargine and thiazolidinediones on plasma lipids in type 2 diabetes : A patient-level pooled analysis. / Chaudhuri, Ajay; Rosenstock, Julio; Digenio, Andres; Meneghini, Luigi; Hollander, Priscilla; McGill, Janet B.; Dandona, Paresh; Ilgenfritz, John; Riddle, Matthew.

In: Diabetes/Metabolism Research and Reviews, Vol. 28, No. 3, 03.2012, p. 258-267.

Research output: Contribution to journalArticle

Chaudhuri, Ajay ; Rosenstock, Julio ; Digenio, Andres ; Meneghini, Luigi ; Hollander, Priscilla ; McGill, Janet B. ; Dandona, Paresh ; Ilgenfritz, John ; Riddle, Matthew. / Comparing the effects of insulin glargine and thiazolidinediones on plasma lipids in type 2 diabetes : A patient-level pooled analysis. In: Diabetes/Metabolism Research and Reviews. 2012 ; Vol. 28, No. 3. pp. 258-267.
@article{794475abae5c4ac681d34717b51f82f8,
title = "Comparing the effects of insulin glargine and thiazolidinediones on plasma lipids in type 2 diabetes: A patient-level pooled analysis",
abstract = "Background: The prevalence of dyslipidaemia and the risk of cardiovascular disease are elevated in patients with type 2 diabetes. This analysis compared the effects of insulin glargine versus thiazolidinediones (TZDs) on lipid profiles. Methods: Patient-level data were pooled from two randomized clinical studies. The population included 552 men and women aged >18years, diagnosed with type 2 diabetes for at least 6months, on metformin and/or sulphonylurea, and with A 1C ≥7.5{\%} and <12.0{\%} at screening. Lipid outcome measures included change from baseline in lipid levels [low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), non-high-density lipoprotein cholesterol (non-HDL-C), total cholesterol, triglycerides, and free fatty acids] and attainment of lipid goals for LDL-C, non-HDL-C, and triglycerides. Results: Both insulin glargine and TZDs improved lipid profiles from baseline values. Compared with TZDs, treatment with insulin glargine led to 7.9{\%} greater reduction in LDL-C (p<0.0003), 7.5{\%} greater reduction in non-HDL-C (p<0.0001), and 7.8{\%} greater reduction in total cholesterol (p<0.0001), whereas the HDL-C increase with TZD was 7.6{\%} greater than that with insulin glargine (p<0.0001). The percentage of patients attaining the lipid goals was comparable between insulin glargine and pioglitazone, but lower for rosiglitazone. Insulin glargine improved glycaemic control more than TZDs; however, insulin glargine caused more hypoglycaemia. Treatment with TZDs caused more weight gain and peripheral oedema. Conclusion: These findings suggest that the favourable effects of insulin glargine on plasma lipid profiles should be considered among the advantages of treatment with insulin glargine as they are for TZDs.",
keywords = "Insulin glargine, Lipids, Thiazolidinediones, Type 2 diabetes",
author = "Ajay Chaudhuri and Julio Rosenstock and Andres Digenio and Luigi Meneghini and Priscilla Hollander and McGill, {Janet B.} and Paresh Dandona and John Ilgenfritz and Matthew Riddle",
year = "2012",
month = "3",
doi = "10.1002/dmrr.1305",
language = "English (US)",
volume = "28",
pages = "258--267",
journal = "Diabetes/Metabolism Research and Reviews",
issn = "1520-7552",
publisher = "John Wiley and Sons Ltd",
number = "3",

}

TY - JOUR

T1 - Comparing the effects of insulin glargine and thiazolidinediones on plasma lipids in type 2 diabetes

T2 - A patient-level pooled analysis

AU - Chaudhuri, Ajay

AU - Rosenstock, Julio

AU - Digenio, Andres

AU - Meneghini, Luigi

AU - Hollander, Priscilla

AU - McGill, Janet B.

AU - Dandona, Paresh

AU - Ilgenfritz, John

AU - Riddle, Matthew

PY - 2012/3

Y1 - 2012/3

N2 - Background: The prevalence of dyslipidaemia and the risk of cardiovascular disease are elevated in patients with type 2 diabetes. This analysis compared the effects of insulin glargine versus thiazolidinediones (TZDs) on lipid profiles. Methods: Patient-level data were pooled from two randomized clinical studies. The population included 552 men and women aged >18years, diagnosed with type 2 diabetes for at least 6months, on metformin and/or sulphonylurea, and with A 1C ≥7.5% and <12.0% at screening. Lipid outcome measures included change from baseline in lipid levels [low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), non-high-density lipoprotein cholesterol (non-HDL-C), total cholesterol, triglycerides, and free fatty acids] and attainment of lipid goals for LDL-C, non-HDL-C, and triglycerides. Results: Both insulin glargine and TZDs improved lipid profiles from baseline values. Compared with TZDs, treatment with insulin glargine led to 7.9% greater reduction in LDL-C (p<0.0003), 7.5% greater reduction in non-HDL-C (p<0.0001), and 7.8% greater reduction in total cholesterol (p<0.0001), whereas the HDL-C increase with TZD was 7.6% greater than that with insulin glargine (p<0.0001). The percentage of patients attaining the lipid goals was comparable between insulin glargine and pioglitazone, but lower for rosiglitazone. Insulin glargine improved glycaemic control more than TZDs; however, insulin glargine caused more hypoglycaemia. Treatment with TZDs caused more weight gain and peripheral oedema. Conclusion: These findings suggest that the favourable effects of insulin glargine on plasma lipid profiles should be considered among the advantages of treatment with insulin glargine as they are for TZDs.

AB - Background: The prevalence of dyslipidaemia and the risk of cardiovascular disease are elevated in patients with type 2 diabetes. This analysis compared the effects of insulin glargine versus thiazolidinediones (TZDs) on lipid profiles. Methods: Patient-level data were pooled from two randomized clinical studies. The population included 552 men and women aged >18years, diagnosed with type 2 diabetes for at least 6months, on metformin and/or sulphonylurea, and with A 1C ≥7.5% and <12.0% at screening. Lipid outcome measures included change from baseline in lipid levels [low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), non-high-density lipoprotein cholesterol (non-HDL-C), total cholesterol, triglycerides, and free fatty acids] and attainment of lipid goals for LDL-C, non-HDL-C, and triglycerides. Results: Both insulin glargine and TZDs improved lipid profiles from baseline values. Compared with TZDs, treatment with insulin glargine led to 7.9% greater reduction in LDL-C (p<0.0003), 7.5% greater reduction in non-HDL-C (p<0.0001), and 7.8% greater reduction in total cholesterol (p<0.0001), whereas the HDL-C increase with TZD was 7.6% greater than that with insulin glargine (p<0.0001). The percentage of patients attaining the lipid goals was comparable between insulin glargine and pioglitazone, but lower for rosiglitazone. Insulin glargine improved glycaemic control more than TZDs; however, insulin glargine caused more hypoglycaemia. Treatment with TZDs caused more weight gain and peripheral oedema. Conclusion: These findings suggest that the favourable effects of insulin glargine on plasma lipid profiles should be considered among the advantages of treatment with insulin glargine as they are for TZDs.

KW - Insulin glargine

KW - Lipids

KW - Thiazolidinediones

KW - Type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=84858110025&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84858110025&partnerID=8YFLogxK

U2 - 10.1002/dmrr.1305

DO - 10.1002/dmrr.1305

M3 - Article

VL - 28

SP - 258

EP - 267

JO - Diabetes/Metabolism Research and Reviews

JF - Diabetes/Metabolism Research and Reviews

SN - 1520-7552

IS - 3

ER -